Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Sign Up to like & getrecommendations! Published in 2018 at "Nature Medicine"
DOI: 10.1038/s41591-018-0115-6
Abstract: Mutations in the gene encoding isocitrate dehydrogenase 2 (IDH2) occur in several types of cancer, including acute myeloid leukemia (AML). In model systems, mutant IDH2 causes hematopoietic differentiation arrest. Enasidenib, a selective small-molecule inhibitor of… read more here.
Keywords: inhibitor; myeloid leukemia; differentiation; acute myeloid ... See more keywords
UPLC-MS/MS for the Herb-Drug Interactions of Xiao-Ai-Ping Injection on Enasidenib in Rats Based on Pharmacokinetics
Sign Up to like & getrecommendations! Published in 2021 at "BioMed Research International"
DOI: 10.1155/2021/6636266
Abstract: Objective To develop and validate a sensitive and rapid ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for the determination of enasidenib in rat plasma and to investigate the effect of Xiao-ai-ping injection (XAPI) on the… read more here.
Keywords: group; ping injection; xiao ping; enasidenib rats ... See more keywords
Real World Use of IDH2- Targeted Inhibitors in a Single Academic Medical Center Experience Since Enasidenib FDA-Approval
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-125135
Abstract: Background Enasidenib, a novel inhibitor of isocitrate dehydrogenase 2 (IDH2), offers targeted therapy to the ~12% of acute myeloid leukemia (AML) patients in which a recurrent IDH2 mutation exists. While currently only FDA approved for… read more here.
Keywords: clinical trial; fda approval; disease; idh2 ... See more keywords